Interactions Between CYP2C9 and UGT1A6 Polymorphisms and Nonsteroidal Anti-Inflammatory Drugs in Colorectal Cancer Prevention

Clinical Gastroenterology and Hepatology

Volumn 4, Issue 7, 2006, Pages 894-901

  Samowitz, Wade S ^a   Wolff, Roger K ^b   Curtin, Karen ^b   Sweeney, Carol ^b   Ma, Khe ni ^b   Andersen, Kristen ^c   Levin, Theodore R ^d   Slattery, Martha L ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYTOCHROME P450 2C9; GLUCURONOSYLTRANSFERASE; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE GLUCURONYLTRANSFERASE ISOENZYME 1A6;

ADULT; AGED; ALLELE; ARTICLE; CANCER PREVENTION; CANCER RISK; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; DOSE RESPONSE; DRUG DNA INTERACTION; DRUG EFFECT; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; WILD TYPE;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARYL HYDROCARBON HYDROXYLASES; ASPIRIN; CASE-CONTROL STUDIES; COLONIC NEOPLASMS; FEMALE; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; IBUPROFEN; MALE; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; POLYMORPHISM, GENETIC; RECTAL NEOPLASMS;

EID: 33745596805     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2006.04.021     Document Type: Article

References (18)

1. Baron J.A., and Sandler R.S. Nonsteroidal anti-inflammatory drugs and cancer prevention. Annu Rev Med 51 (2000) 511-523
2. Leemann T.D., Transon C., Bonnabry P., et al. A major role for cytochrome P450TB (CYP2C subfamily) in the actions of non-steroidal antiinflammatory drugs. Drugs Exp Clin Res 19 (1993) 189-195
3. Hutt A.J., Caldwell J., and Smith R.L. The metabolism of aspirin in man. a population study. Xenobiotica 16 (1986) 239-249
4. Chan A.T., Tranah G.J., Giovannucci E.L., et al. Genetic variants in the UGT1A6 enzyme, aspirin use, and the risk of colorectal adenoma. J Natl Cancer Inst 97 (2005) 457-460
5. Ciotti M., Marrone A., Potter C., et al. Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase. pharmacological implications. Pharmacogenetics 7 (1997) 485-495
6. Takanashi K., Tainaka H., Kobayashi K., et al. CYP2C9 Ile359 and Leu359 variants. enzyme kinetic study with seven substrates. Pharmacogenetics 10 (2000) 95-104
7. Chan A.T., Tranah G.J., Giovannucci E.L., et al. A prospective study of genetic polymorphisms in the cytochrome P-450 2C9 enzyme and the risk for distal colorectal adenoma. Clin Gastroenterol Hepatol 2 (2004) 704-712
8. Bigler J., Whitton J., Lampe J.W., et al. CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk. Cancer Res 61 (2001) 3566-3569
9. Crespi C.L., and Miller V.P. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH. cytochrome P450 oxidoreductase. Pharmacogenetics 7 (1997) 203-210
10. McGreavey L.E., Turner F., Smith G., et al. No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPARdelta and PPARgamma act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma. Pharmacogenet Genomics 15 (2005) 713-721
11. Slattery M.L., Samowitz W., Hoffman M., et al. Aspirin, NSAIDs, and colorectal cancer. possible involvement in an insulin-related pathway. Cancer Epidemiol Biomarkers Prev 13 (2004) 538-545
12. Slattery M.L., Potter J., Caan B., et al. Energy balance and colon cancer-beyond physical activity. Cancer Res 57 (1997) 75-80
13. Edwards S., Slattery M.L., Mori M., et al. Objective system for interviewer performance evaluation for use in epidemiologic studies. Am J Epidemiol 140 (1994) 1020-1028
14. Dorado P., Berecz R., Norberto M.J., et al. CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers. Eur J Clin Pharmacol 59 (2003) 221-225
15. Peters W.H., te Morsche R.H., and Roelofs H.M. Combined polymorphisms in UDP-glucuronosyltransferases 1A1 and 1A6. implications for patients with Gilbert's syndrome. J Hepatol 38 (2003) 3-8
16. Castillo M., and Smith P.C. Disposition and reactivity of ibuprofen and ibufenac acyl glucuronides in vivo in the rhesus monkey and in vitro with human serum albumin. Drug Metab Dispos 23 (1995) 566-572
17. Kuehl G.E., Lampe J.W., Potter J.D., et al. Glucuronidation of nonsteroidal anti-inflammatory drugs. identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos 33 (2005) 1027-1035
18. Rosenberg L., Palmer J.R., Zauber A.G., et al. A hypothesis. nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 83 (1991) 355-358